Physician profile
Brian Paul Dudgeon
NPI 1780603407
$2,749.16
in general payments reported to CMS, 2019-2025
28 companies · $538 in 2025
The $538 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $183 · 2021: $146 · 2022: $478 · 2023: $422 · 2024: $494 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $638.70 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $304.36 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $295.73 | 2019-2025 | |
| Sobi, INC | $165.80 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $140.22 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $138.16 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Baxter Healthcare | $117.60 | 2022 | |
| Welch Allyn | $117.60 | 2021 | |
| Sanofi Pasteur INC. | $93.85 | 2019-2025 | |
| Tris Pharma INC | $78.80 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $66.52 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.22 | 2020-2022 | |
| Neos Therapeutics, LP | $52.12 | 2020-2024 | Adzenys Xr-Odt |
| Verrica Pharmaceuticals INC. | $48.37 | 2024-2025 | Ycanth |
| Glaxosmithkline, LLC. | $45.09 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $44.98 | 2022-2023 | Flumist Quadrivalent |
| Adlon Therapeutics L.P. | $41.80 | 2019-2020 | |
| Kaleo, INC. | $40.57 | 2019-2022 | |
| Shire North American Group INC | $39.82 | 2019 | |
| Supernus Pharmaceuticals, INC. | $37.12 | 2023-2025 | Qelbree, Qelbree |
| Alk-Abello, INC | $33.25 | 2025 | Neffy, Grastek, Odactra |
| Hologic Sales and Service, LLC | $32.41 | 2022-2024 | Aptima |
| Vertical Pharmaceuticals, LLC | $32.37 | 2019-2025 | Relexxii |
| Genentech USA, INC. | $28.13 | 2019-2020 | |
| Mission Pharmacal Company | $18.54 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.46 | 2024 | |
| Mylan Pharmaceuticals INC. | $15.42 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dudgeon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.